These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

104 related articles for article (PubMed ID: 22548530)

  • 1. Gutter method: noninvasive management of ingrown nails caused by epidermal growth factor inhibitor treatment.
    Harada K; Yamaguchi M; Miyajima S; Kawamura T; Shibagaki S; Shimada S
    Clin Exp Dermatol; 2012 Aug; 37(6):703-4. PubMed ID: 22548530
    [No Abstract]   [Full Text] [Related]  

  • 2. Severe acneiform skin reaction during therapy with erlotinib (Tarceva), an epidermal growth factor receptor (EGFR) inhibitor.
    Eames T; Landthaler M; Karrer S
    Eur J Dermatol; 2007; 17(6):552-3. PubMed ID: 17951151
    [No Abstract]   [Full Text] [Related]  

  • 3. Successful treatment of pyogenic granulomas following gefitinib therapy with partial matricectomy and phenolization.
    Dika E; Balestri R; Vaccari S; Alessandro Fanti P; Misciali C; Patrizi A
    J Dermatolog Treat; 2009; 20(6):374-5. PubMed ID: 19954397
    [No Abstract]   [Full Text] [Related]  

  • 4. Irreversible ototoxicity associated with the use of erlotinib in a patient with pancreatic cancer.
    Koutras AK; Mastronikolis NS; Evans TR; Papadeas ES; Makatsoris T; Kalofonos HP
    Acta Oncol; 2008; 47(6):1171-3. PubMed ID: 18615326
    [No Abstract]   [Full Text] [Related]  

  • 5. A simple and practical method in treatment of ingrown nails: splinting by flexible tube.
    Nazari S
    J Eur Acad Dermatol Venereol; 2006 Nov; 20(10):1302-6. PubMed ID: 17062049
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Erlotinib-induced trichomegaly in a male patient with pancreatic cancer.
    Saif MW; Gnanaraj J
    Cutan Ocul Toxicol; 2010 Mar; 29(1):62-6. PubMed ID: 19954400
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Phenol 8% solution for the treatment of epidermal growth factor receptor inhibitor-induced periungual pyogenic granulomas.
    Panariello L; Caro G; Bianca D; Fabbrocini G
    G Ital Dermatol Venereol; 2015 Dec; 150(6):755-6. PubMed ID: 26513046
    [No Abstract]   [Full Text] [Related]  

  • 8. Generalized xerotic dermatitis with neutrophilic spongiosis induced by erlotinib (Tarceva).
    Lübbe J; Masouyé I; Dietrich PY
    Dermatology; 2008; 216(3):247-9. PubMed ID: 18182820
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Facial hypertrichosis and trichomegaly developing in patients treated with the epidermal growth factor receptor inhibitor erlotinib.
    Vergou T; Stratigos AJ; Karapanagiotou EM; Matekovits AE; Dilana KD; Tsimboukis S; Antoniou C; Chasapi V; Syrigos KN
    J Am Acad Dermatol; 2010 Aug; 63(2):e56-8. PubMed ID: 20633793
    [No Abstract]   [Full Text] [Related]  

  • 10. The Koebner-phenomenon in epidermal growth factor receptor inhibitor-induced cutaneous adverse effects.
    Gerber PA; Enderlein E; Homey B
    J Clin Oncol; 2008 Jun; 26(16):2790-2. PubMed ID: 18509193
    [No Abstract]   [Full Text] [Related]  

  • 11. [Erlotinib-induced acneiform rash not affecting previously irradiated skin].
    Eguren C; Domínguez-Fernández I; Santiago-Sánchez-Mateos DI; García-Díez A
    Actas Dermosifiliogr; 2010 Mar; 101(2):186-7. PubMed ID: 20223168
    [No Abstract]   [Full Text] [Related]  

  • 12. Nursing management of epidermal growth factor receptor inhibitor-induced toxicities.
    Dunsford J
    Clin J Oncol Nurs; 2008 Jun; 12(3):405-7. PubMed ID: 18515238
    [No Abstract]   [Full Text] [Related]  

  • 13. Ocular findings in patients with solid tumours treated with the epidermal growth factor receptor tyrosine kinase inhibitor gefitinib ('Iressa', ZD1839) in Phase I and II clinical trials.
    Tullo AB; Esmaeli B; Murray PI; Bristow E; Forsythe BJ; Faulkner K
    Eye (Lond); 2005 Jul; 19(7):729-38. PubMed ID: 15688060
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Papulopustular drug eruption due to an epidermal growth factor receptor inhibitors, erlotinib and cetuximab.
    Bragg J; Pomeranz MK
    Dermatol Online J; 2007 Jan; 13(1):1. PubMed ID: 17511934
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Suture-secured modified gutter splint method for the conservative treatment of ingrown toenails.
    Erdem O; Dağtaş BB; Koku Aksu AE; Göktay F
    J Am Acad Dermatol; 2023 Jun; 88(6):e301. PubMed ID: 33582261
    [No Abstract]   [Full Text] [Related]  

  • 16. Density of Demodex folliculorum in patients receiving epidermal growth factor receptor inhibitors.
    Gerber PA; Kukova G; Buhren BA; Homey B
    Dermatology; 2011; 222(2):144-7. PubMed ID: 21346311
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Erlotinib and maintenance therapy of non-small cell lung cancer. Inadequate assessment; authorisation unjustified.
    Prescrire Int; 2011 Oct; 20(120):234. PubMed ID: 21970082
    [No Abstract]   [Full Text] [Related]  

  • 18. Usefulness of Noninvasive Management With the Gutter Method for Epidermal Growth Factor Receptor Inhibitor-Induced Paronychia, Pyogenic Granuloma-Like Lesion, and Ingrown Nail.
    Agematsu A; Kamata M; Namiki K; Yabuuchi Y; Nagata M; Tada Y
    JAMA Dermatol; 2022 May; 158(5):583-585. PubMed ID: 35416917
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Author reply: To PMID 22584020.
    Molina-Prat N; Saint-Jean A; Sainz de la Maza M
    Ophthalmology; 2013 May; 120(5):1104-5. PubMed ID: 23642746
    [No Abstract]   [Full Text] [Related]  

  • 20. Cutaneous adverse effects during therapy with an epidermal growth factor receptor (EGFR) inhibitor.
    Santoro F; Cozzani E; Parodi A
    J Dermatolog Treat; 2006; 17(3):160-1. PubMed ID: 16854757
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.